Press Releases WuXi AppTec Co., Ltd. Hong Kong S.E.

Equities

2359

CNE100003F19

Market Closed - Hong Kong S.E. Other stock markets 04:08:34 2024-07-17 am EDT			5-day change	1st Jan Change
29.3 ^HKD	+2.99%		+6.16%	-63.12%

Jun. 06	Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	RE
Jun. 01	US lawmakers ask FBI for briefing on GenScript Biotech's links to China	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Planning For The BIOSECURE Act	Apr. 03	AQ
The BIOSECURE Act: Proposed New Legislation Could Affect U.S. Companies' Plans To Contract With Chinese Biotechnology Companies	Mar. 21	AQ
Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security	Feb. 24	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI for Advanced Melanoma	Feb. 21	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma	Feb. 21	AQ
WuXi AppTec : Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth	23-10-30	PU
WuXi AppTec : 2023 Third Quarterly Results Presentation	23-10-30	PU
Promega Corporation - DNA-Encoded Libraries and NanoBRET Target Engagement Assays Accelerate Drug Discovery	23-08-02	AQ
WuXi AppTec : 2023 Interim Results Presentation	23-07-31	PU
WuXi AppTec : First Quarter 2023 Results Presentation	23-04-24	PU
WuXi AppTec : 2022 Annual Results Presentation	23-03-23	PU
WuXi AppTec : Named “Industry Mover” in S&P Global Sustainability Yearbook 2023	23-02-15	PU
Delivering on the Promise of New Modalities: An Interview with Maria Luisa Pineda, CEO and Co-founder, Envisagenics	23-01-16	PU
WuXi AppTec : 2023 J.P. Morgan Presentation	23-01-11	PU
Delivering on the Promise of New Modalities: An Interview with SJ Lee, CEO, Orum Therapeutics	23-01-06	PU
WuXi STA and Multiply Labs announce partnership and successfully deploy robotic manufacturing system for personalized drugs	22-12-02	AQ
WuXi AppTec : 2022 Third Quarterly Results Presentation	22-10-26	PU
Delivering on the Promise of New Modalities: An Interview with Christopher Thanos, President, CEO & Co-Founder, Actym Therapeutics, Inc.	22-10-12	PU
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility	22-09-27	AQ
Delivering on the Promise of New Therapies for Rare Diseases: An Interview with Lili Mao, Director of Clinical Development Unit and Head of Project Management Office at GEXVal	22-09-19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases WuXi AppTec Co., Ltd. Hong Kong S.E.

Equities

2359

CNE100003F19

Press Releases

Filters